A Multicenter, Randomized, Double-blind, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of WXSH0102 Tablets in the Treatment of Vulvovaginal Candidiasis (VVC)

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study is a multicenter, randomized, double-blind, active-controlled, dose-ranging clinical trial designed to evaluate the efficacy and safety of the investigational drug compared to the active comparator in the treatment of vulvovaginal candidiasis. The trial consists of three phases: screening/enrollment (D-3 to D-1), treatment period (D1 to D3), and follow-up period (D4, D11±2, D25±3). Eligible subjects in this study will be randomized in a 1:1:1:1 ratio to three investigational drug arms with different dosing regimens and one active control arm. Specifically, Group A will receive WXSH0102 tablets with 1400 mg on the first day followed by a maintenance dose of 700 mg for two consecutive days, Group B will receive WXSH0102 tablets with 1000 mg on the first day followed by a maintenance dose of 500 mg for two consecutive days, Group C will receive WXSH0102 tablets with 600 mg on the first day followed by a maintenance dose of 300 mg for two consecutive days, and Group D (active control group) will receive fluconazole capsules for only one day on D1. All medications will be administered orally.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 64
Healthy Volunteers: t
View:

• The subjects understood and voluntarily signed the informed consent Form (ICF), and were willing and able to comply with the study protocol.

• Female participants who signed ICF at the age of 18-64 years (including the cut-off value) and had sexual intercourse;

• Participants were diagnosed with VVC and met each of the following criteria: a. At screening, the total score on the VVC scale was ≥4 and at least two of the symptoms or signs on the VVC scale were present; b. A vaginal discharge sample collected at screening was Gram stain positive for Candida (hypha/pseudohypha/budding); c. Vaginal pH ≤4.5; Symptoms: vulvovaginal itching, vulvar burning pain, dyspareunia and urination pain, excessive secretion, secretion is tofu residue like; Physical signs: gynecological examination showed vulvar hyperemia and edema, which may be accompanied by scratches. In severe cases, chapped skin, exfoliation and even erosion could be seen. Vaginal mucosa was hyperemic, vaginal secretion was curd or tofu residue like;

• Subjects who are capable of oral administration;

• For the duration of the study, participants agreed to abstain from sexual activity and to use the condom throughout sexual activity.

Locations
Other Locations
China
251 Yaojiayuan Road, Chaoyang District, Beijing
NOT_YET_RECRUITING
Beijing
Beijing Obstetrics and Gynecology Hospital
RECRUITING
Beijing
Contact Information
Primary
Zhaohui Liu, professor
23662161@qq.com
13701118639
Time Frame
Start Date: 2025-01-13
Estimated Completion Date: 2025-07-31
Participants
Target number of participants: 108
Treatments
Experimental: Arm A : WXSH0102 Day1 1400 mg Day2-3 700
Arm A will receive WXSH0102 tablets with a loading dose of 1400 mg on the first day followed by a maintenance dose of 700 mg for two consecutive days
Experimental: Arm B : WXSH0102 Day1 1000 mg Day2-3 500 arm
Arm B will receive WXSH0102 tablets with a loading dose of 1000 mg on the first day followed by a maintenance dose of 500 mg for two consecutive days
Experimental: C : WXSH0102 Day1 600 mg Day2-3 300
Arm C will receive WXSH0102 tablets with a loading dose of 600 mg on the first day followed by a maintenance dose of 300 mg for two consecutive days
Active_comparator: Arm D: fluconazole
Arm D (active control group) will receive fluconazole capsules for only one day on D1
Related Therapeutic Areas
Sponsors
Leads: Cisen Pharmaceutical CO., LTD.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials